Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJUQT1)

• Drug Name: L-685,818 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 445642
  TTD Drug ID: DMJUQT1

Molecule-Related Drug Atlas

Drug(s) Targeting Calcineurin (PPP3CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrolimus	DMZ7XNQ	Graft-versus-host disease	4B24	Approved	[3]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[4]
Pimecrolimus	DMZLGRB	Atopic dermatitis	EA80	Approved	[5]
Voclosporin	DMWIJTN	Lupus nephritis	4A40.0Y	Approved	[6]

Drug(s) Targeting Opioid receptor kappa (OPRK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nalbuphine	DMOSQGU	Pain	MG30-MG3Z	Approved	[7]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[8]
CHLOROXINE	DMFZBMQ	Erythema	ME64.0	Approved	[9]
Difelikefalin	DMHZBEO	Pruritus	EC90	Approved	[10]
Dezocine	DMJDB0Y	Pain	MG30-MG3Z	Approved	[11]
Asimadoline	DMND3AB	Diarrhea-predominant irritable bowel syndrome	DD91.01	Phase 3	[12]
JNJ 67953964	DMJ8Y5N	Major depressive disorder	6A70.3	Phase 3	[13]
PHN-131	DM1SV8I	Pain	MG30-MG3Z	Phase 2/3	[14]
CR-845	DMJYTUQ	Pain	MG30-MG3Z	Phase 2/3	[15]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcineurin (PPP3CA)	TTA4LDE	PP2BA_HUMAN	Inhibitor	[2]
Opioid receptor kappa (OPRK1)	TTQW87Y	OPRK_HUMAN	Antagonist	[1]

References

• [1] FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9.
• [2] Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 Mar;44(3):739-46.
• [3] Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
• [4] Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45.
• [5] Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [9] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
• [12] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [13] Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handb Exp Pharmacol. 2022;271:473-491.
• [14] Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
• [15] Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
• [16] Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.